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Abstract
Drug-placebo differences (effect-sizes) in controlled trials of antidepressants for major depressive episodes have
declined for several decades, in association with selectively increasing clinical improvement associated with pla-
cebo-treatment. As these trends require adequate explanation, we tested the hypothesis that decreasing trial-
dropout rates may be an important contributor. We gathered reports of peer-reviewed, placebo-controlled trials
of antidepressants (1980–2011) by computerized literature searching, and applied meta-analysis, meta-regression
and multiple linear regression methods to evaluate associations of dropout rates and other factors of interest, to
reporting year and reported efﬁcacy [standardized mean drug-placebo difference (SMD) as Hedges’ g-statistic].
In 56 trials meeting inclusion and exclusion criteria, we conﬁrmed signiﬁcant overall efﬁcacy of antidepressants
but declining drug-placebo contrasts over the past three decades. Among other changes, there was a correspond-
ing increase in placebo-associated improvement with a decline in placebo-dropout rate, mainly for lack
of efﬁcacy. These effects were found only when last-observation-carried-forward (LOCF) analyses were
used. Other trial-design and subject factors, including drug-responses and drug-dropout rates, were much less
associated with efﬁcacy. We propose that declining placebo-dropout rates ascribed to inefﬁcacy combined
with use of LOCF analyses led to increasing improvement in placebo-arms that contributed to declining
antidepressant–placebo contrasts in controlled treatment trials since the 1980s.
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Introduction
Antidepressants are currently a standard treatment for
major depressive disorder, supported by comparisons
to placebo treatment under blinded conditions in rando-
mized controlled trials (RCTs) (Baldessarini, 2013).
Although development, testing and licensing of new
antidepressants has continued apace over the past sev-
eral decades, several reviews have identiﬁed a decline
in antidepressant-placebo differences (effect-size) in anti-
depressant trials, with a substantial proportion of trials
failing statistically to distinguish responses to treatment
with antidepressants vs. placebo (Walsh et al., 2002;
Khan et al., 2003a, 2010; Undurraga and Baldessarini,
2012; Baldessarini, 2013). These trends have been asso-
ciated with selective increases in clinical responses
associated with placebos and stable responses to drug-
treatment, with corresponding decreases in drug-placebo
differences (Walsh et al., 2002; Khan et al., 2003a, 2010;
Undurraga and Baldessarini, 2012; Undurraga et al.,
2013).
Effect-sizes based on drug-placebo differences for
speciﬁc drugs usually are pooled and compared in com-
prehensive, systematic reviews employing meta-analysis
(Hedges, 1981; Borenstein et al., 2009). Trials considered
for such reviews differ in design and conduct as well as
in characteristics of participants and study-sites, assess-
ment methods, duration, dosing of drugs and outcome
measures. Such heterogeneity may contribute to differ-
ences in results among trials of even nominally identical
treatments, greatly complicating efforts to determine
best estimates of effect-sizes and to compare speciﬁc treat-
ments by relative efﬁcacy. Attempts have been made to
identify methodological features and patient character-
istics that contribute to heterogeneity and may account
for inter-trial variability and the steady decline of effect-
size in antidepressant trials over the years. Proposed
factors include trial-duration (Khan et al., 2010; Henkel
et al., 2012), trial complexity associated with the number
of participating sites and subjects (Khan et al., 2004;
Henkel et al., 2012; Undurraga and Baldessarini, 2012)
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minimum required depression scores or other indications
of baseline illness-severity for inclusion (Khan et al., 2002,
2007; Kirsch et al., 2008), pre-trial placebo washout of pre-
vious drugs (Lee et al., 2004), depression rating-scale em-
ployed (Khan et al., 2010), number of treatment arms or
probability of randomization to placebo (Khan et al., 2004;
Papakostas and Fava, 2009), frequency of assessments
(Iovieno et al., 2011), and ﬂexible vs. ﬁxed dosing (Khan
et al., 2003b). Although many of these factors may well
contribute to variance of trial-outcomes, it is our im-
pression that the decrease of effect-size across years, in
particular, remains to be explained adequately.
A particularly striking change in antidepressant trials
has been a steady and selective increase in reported re-
sponses among subjects randomized to placebo (Walsh
et al., 2002; Undurraga and Baldessarini, 2012). This in-
crease might be related to changing characteristics of
patient samples or trial methods. A possible, speciﬁc con-
tributor may be change in dropout rates over the past
decades. Individual trials usually analyse the data on an
intention-to-treat (ITT) basis, so that virtually all rando-
mized subjects are included in analyses of symptomatic
change between trial intake and protocol endpoint
(Tierney and Stewart, 2005). However, subjects tend to
leave trials prematurely for various reasons that typically
are dissimilar in drug (usually poor tolerability) and
placebo arms (typically, lack of efﬁcacy) of trials (Little
et al., 2012). A particularly prevalent way to conduct
an ITT analysis is to apply the last observation carried for-
ward (LOCF) method. This method can be problematic,
especially when there are systematic differences in the tim-
ing and reasons for dropping out in different trial-arms
(Hennen, 2003; Lane, 2008; Wittes, 2009; Little et al.,
2012). Dropouts combined with LOCF analyses can distort
trial outcomes in trials of antipsychotic drugs (Kemmler
et al., 2005; Rabinowitz and Davidov, 2008; Hutton
et al., 2012), but their effects are less well studied in trials
of antidepressants.
Given these considerations, we hypothesized that
changes in the proportion of dropouts in antidepressant
trials, particularly in placebo-arms, in combination with
LOCF methods for ITT endpoint analysis, may contribute
signiﬁcantly to declining antidepressant-placebo differ-
ences observed in meta-analyses of antidepressant trials
over the past several decades. This hypothesis is en-
couraged by the observation that the LOCF method
may underestimate placebo-associated responses in anti-
depressant trials, due to leaving trials early with less
chance of spontaneous clinical improvement (Gomeni
et al., 2009). That is, more and longer retention in placebo-
treatment should lead to greater spontaneous improve-
ment, given the time-limited nature of most acute
episodes of major depressive disorder. In turn, increased
improvements with placebo would yield smaller drug-
placebo contrasts, especially if drug-associated retention
were longer. To test this hypothesis, we quantiﬁed
changes of dropout rates in both placebo and
antidepressant arms of a large, representative sample of
peer-reviewed, placebo-controlled trials of antidepres-
sants from the 1980s to the present, and assessed reported
changes in improvements in depressive symptoms be-
tween antidepressant and placebo groups.
Method
Search strategy
We systematically sought ﬁndings from RCTs of antide-
pressant drugs in major depression in peer-reviewed
reports since 1980. The search methods were detailed pre-
viously (Undurraga and Baldessarini, 2012), and con-
sisted of a computerized literature searching of Medline,
CINAHL, Cochrane and PsycINFO medical research
literature databases. Search-terms included individual
generic names of all clinically employed antidepressants
with regulatory approval in the US, plus ﬂuvoxamine, for
treatment of acute episodes of major depression, terms
for pharmacological classes of antidepressants (sero-
tonin-reuptake inhibitors, tricyclic antidepressants and
others), as well as ‘major depressive disorder’ and ‘de-
pression.’ In addition, reference citations in reports and
reviews on antidepressant efﬁcacy were hand-searched
for additional, relevant reports.
Eligibility and study selection
Data considered were limited to those provided in peer-
reviewed reports of randomized, placebo-controlled,
monotherapy RCTs in acute episodes of adult unipolar
major depressive disorder (or with <10% bipolar de-
pressed subjects). Studies with up to 10% bipolar subjects
were considered because in earlier studies (mainly in the
1980s) inclusion required ‘major depression’ without
necessarily excluding cases of bipolar depression. All sub-
jects were diagnosed by standard international criteria
(DSM-III, III-R, or -IV, ICD-9 or -10 or RDC), as reported
between 1980 and 2011. Since our aim was to test for
trends over time in comparable trials, and not to quantify
efﬁcacy, we did not attempt to acquire data from reports
not based on peer review or not published, particularly
since access to such ﬁndings, especially from earlier
trials, is likely to be incomplete. In addition, we did not
include drugs with questionable efﬁcacy (e.g. hypericum,
gepirone) or without regulatory approval in the US
(e.g., agomelatine, reboxetine) (Baldessarini 2013). Since
meta-analyses of antidepressant trials identifying a de-
crease in effect-sizes over the years (Walsh et al., 2002;
Khan et al., 2010; Undurraga and Baldessarini, 2012)
included outcomes based almost entirely on intention-
to-treat (ITT) analyses, these were therefore an inclusion
criterion for this study. ITT analysis seeks to include all
subjects randomized to all trial treatment-arms, and typi-
cally considers outcomes among all subjects with at least
one post-randomization assessment (Tierney and Stewart,
2005). We deﬁned ITT as all subjects with at least one
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post-baseline assessment at least one week after randomi-
zation. Dropout rates from placebo and antidepressant
trial-arms, and their proposed causes, also were recorded.
Abstracts of initially identiﬁed reports were screened for
possible relevance, veriﬁed by independent review of
full-texts by two investigators who selected trials in-
cluded for analysis, based on their meeting inclusion/ex-
clusion criteria, by consensus.
Outcome measures
As an outcome measure of treatment-response, we
employed the standardized mean difference [(SMD) as
Hedges’ g-statistic] of scores on standard depressive
symptom rating-scales between intake and exit points in
each trial for paired-comparisons of symptomatic changes
associated with antidepressant and placebo (Hedges,
1981; Borenstein et al., 2009). Rating scales considered
were the 17- or 21-item versions of the Hamilton De-
pression Rating Scale (HDRS; Hamilton, 1967), or the
Montgomery-Åsberg Depression Rating Scale (MADRS;
Montgomery and Åsberg, 1979).
Retrieved data
Abstracted data from drug and placebo arms of trials in-
cluded efﬁcacy, with computed SMD, total dropout rates,
as well as rates ascribed to lack of efﬁcacy, intolerability
or adverse events, or miscellaneous other factors. In
order to test for independent associations of dropout
rates with effect-size (SMD), we also considered several
methodological factors reported to be associated with
trial outcomes or otherwise of plausible interest, as sum-
marized in the introduction. These included planned
trial-duration, number of participating subjects and colla-
borating sites, baseline illness-severity, symptom rating-
scale employed, total daily antidepressant dose (as
imipramine-equivalent mg/d [Baldessarini, 2013]), as
well as average age and proportion of male or female par-
ticipants. Because the number of studies reporting re-
quired information needed was limited, we restricted
the number of trial features and patient characteristics in-
cluded in reported analyses.
Data analyses
To manage data from trials involving multiple compari-
sons, trials with more than one antidepressant-arm were
pooled into a single drug-arm by weighted-averaging
(Caldwell et al., 2005). When arms with different doses
of the same drug were employed, a single arm was
made by averaging the depression ratings and changes
and assuming a mean dose of drug (both weighted by
subject-count). Linear regression was used to quantify
temporal trends in dropout rates and other factors over
the past three decades. We employed random-effects
meta-analytic modelling, with SMD (g-statistic) as the
outcome measure, to test for drug-placebo differences
in clinical change (Hedges, 1981; Borenstein et al., 2009).
Changes in depression ratings with drug or placebo treat-
ment were standardized by subject-counts, and variance
was standard deviation (SD) reported, calculated or im-
puted from pooled SD from all trials (Furukawa et al.,
2006). Dropout rates were tested for independent associ-
ation with SMD using meta-regression analysis, including
reporting year as well as other factors with at least
suggestive associations (p40.10). Egger’s test was used
to test for effects of small studies or possible publication
bias (Egger et al., 1997).
Endpoint-analysis based only on trial protocol-
completers is biased by omitting subjects dropping out
of trials prematurely, and potentially also by imputing
missing values at later times by LOCF analysis. To evalu-
ate the inﬂuence of these methods, we included a post-hoc
analysis using trials that reported both completer and
LOCF analyses.
Averaged data are reported as means±SD, as medians
with interquartile range (IQR; especially for non-normally
distributed measures), or as measures with 95% conﬁ-
dence intervals (CI), as noted. Analyses were performed
with commercial software (Stata.10®, StataCorp, College
Station, TX; Statview 5.0®, SAS Institute, Cary, NC).
Results
Electronic and hand searching yielded 2437 potentially
relevant reports appearing between 1980 and 2011.
Based on reviewing titles and abstracts, 179 reports initi-
ally appeared to be potentially eligible for analysis.
Subsequent exclusions (123/179) were for the following
reasons: [a] 17 studies involved <20 patients/arm; [b] 17
included >10% of subjects with diagnoses other than non-
bipolar major depressive episode; [c] 11 involved special
populations (such as juvenile or geriatric patients); [d] 4
did not include a placebo control arm; [e] 19 did not
allow an ITT analysis; [f] 21 did not provide information
required to calculate SMD; [f] 12 represented subpopu-
lations of trials already included; and [g] another 22
did not provide adequate information on dropouts or rea-
sons for dropout. Overall 56 trials, corresponding to 175
treatment-arms, met all study inclusion/exclusion criteria
and were analysed. In 24 of the 56 trials, two antidepres-
sant arms were condensed into one. Salient characteristics
and references of the 56 trials are summarized in an
Appendix (Supplementary Table S1).
Studies analysed included a total of 17189 consenting,
adult, depressed subjects randomized to either an active
antidepressant (n=11349) or a placebo (n=5840). Most
trials (87.0%) involved only outpatients, and 95.6%
had pharmaceutical sponsorship. Three trials (5.4% of
trials, 0.2% of subjects) included <10% bipolar depressed
patients. All trials employed LOCF methods to deal
with missing data. Owing to different trial-arm counts
per trial, the overall median chance of randomization
to placebo was 0.33 (range: 0.14–0.50), and median
trial-duration was 8.0 (4.0–13) weeks, following 7.0
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(4–16) days of preliminary placebo-washout of previous
treatments in the 82.1% of trials reporting such infor-
mation. Drugs considered (n=14), ranked by frequency of
testing, were: imipramine (18.0%), venlafaxine (15.0%),
ﬂuoxetine (12.3%), desvenlafaxine (10.0%), paroxetine
(10.0%), duloxetine (7.50%), amitriptyline (5.00%), escita-
lopram (5.00%), sertraline (5.00%), bupropion (3.75%),
citalopram (3.75%), ﬂuvoxamine (1.25%), mirtazapine
(1.25%), and trazodone (1.25%). Some trials with multiple
arms also involved agents such as hypericum and gepir-
one not approved for depression and not considered in
the present study.
Trials analysed included a median (range) size of 290
(52–717) subjects from a median of 12 (1–69) collaborating
sites; 63% (37–85%) of subjects were women, and median
age was 40.6 (34.4–56.0) years. Clinical ratings involved
the 17- or 21-item versions of the HDRS (51.8 and 33.9%)
or the MADRS (14.3%), with a median of 3 (2–5) assess-
ments and depression-ratings/month (6 [4–10] total).
Median baseline-depression scores (based on majority-use
of the 17-item HDRS only, for comparability) were 23.1
(17.7–26.4) among subjects randomized to drugs and
23.4 (17.2–26.6) with placebo. Baseline depression-severity
did not change signiﬁcantly over the years of reporting,
controlling for depression rating scales employed (slope
[β] =−0.065 [−0.147 to +0.018]; t=1.57, p=0.12).
Trends in efﬁcacy
Based on random-effects meta-analysis, as expected
(Undurraga and Baldessarini, 2012), there was an overall,
highly signiﬁcant, drug-placebo difference in
improvement of depression ratings across the 56 trials
of 14 antidepressant drugs. Pooled SMD (95% CI) was
0.372 ([0.328–0.415]; z=16.8, p<0.0001). We also
conﬁrmed a strong decline in effect-size (SMD) over
years of reporting (slope [β] =−0.014 [CI: −0.019 to
0.010]; t=6.55, p<0.0001, Table 1a). This decline was asso-
ciated with little change in antidepressant-associated
responses over the era (β=+0.008 [−0.002 to +0.017], t=
1.65, p=0.10), but with major and consistent increases in
responses in placebo-arms (β=+0.024 [+0.014 to +0.034],
t=4.81, p<0.0001). These trends were similar and signiﬁ-
cant across drug-types (TCAs, SRIs and SNRIs), with
decreasing effect sizes, stable drug-associated effects
and increasing placebo-associated effects over time (data
not shown). Effects of other factors associated with
SMD are summarized in Table 1b: the most strongly asso-
ciated factor was placebo dropout for lack of efﬁcacy, and
later reporting years had signiﬁcantly lower SMD,
whereas trial duration and size were not signiﬁcantly
associated with effect-size.
Trends in dropout rates
In addition to increases in trial-size and duration over the
years, there were particularly large decreases in dropout
rates over years (Table 1a). Dropout rates for all causes
declined highly signiﬁcantly across reporting years (over-
all slope function, β=−1.23 [95%CI: −1.56 to −0.897]; t=
7.41, p<0.0001). Dropout rates in the ﬁrst decade aver-
aged 39.8±11.1% with antidepressants, and 47.7±13.2%
with placebo, compared to 24.3±8.27% and 24.0±9.04%,
respectively, in the ﬁnal decade sampled. These rates
Table 1. Preliminary analysis of factors associated with reporting year and effect-size in controlled trials of antidepressants
a. Linear regression for factors of interest vs. year of reporting (n=56)
Factors Slope (β ) [95% CI] t-score p-value
Subject age (years) +0.067 [−0.048 to +0.183] 1.17 0.25
Women/trial (%) +0.281 [−0.013 to +0.574] 1.92 0.06
Sample size (N) +8.00 [+1.97 to +14.0] 2.66 0.01
Trial duration (weeks) +0.110 [+0.052 to +0.169] 3.78 0.0004
Dose (IMI-eq mg/day) +0.824 [−2.41 to +4.06] 0.51 0.61
Dropout rate (%)
Overall −1.23 [−1.56 to −0.897] 7.41 <0.0001
Drug −1.01 [−1.36 to −0.652] 5.68 <0.0001
Placebo −1.54 [−1.95 to −1.12] 7.37 <0.0001
b. Meta-regression analysis for factors associated with effect-size (n=56)
Factors Slope (β) [95% CI] t-score p-value
Total dropout rate (%)
Antidepressants −0.004 [−0.01 to +0.001] 1.47 0.15
Placebo +0.007 [+0.002 to +0.012] 2.89 0.006
Reporting year −0.009 [−0.016 to −0.002] 2.68 0.01
Trial duration (weeks) +0.006 [−0.017 to +0.029] 0.54 0.59
Sample size (N) <–0.001 [−0.0002 to +0.0002] 0.17 0.87
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declined signiﬁcantly and similarly in antidepressant
arms (β=−1.01 [−1.36 to −0.652]), but even more in
placebo-arms (β=−1.54 [−1.95 to −1.12]) of trials. The
proportion of dropouts from placebo-arms was correlated
with that from the drug-arm (β=1.03 [95%CI: 0.81 to
−1.26]; t=9.31, p<0.0001). However, dropout rates var-
ied markedly between drug and placebo arms by cited
causes, including lack of efﬁcacy, intolerability or adverse
effects and miscellaneous other reasons (Fig. 1). In
antidepressant-arms, dropouts for intolerability declined
most (slope [β] =−0.630 [−0.909 to −0.352], and less for
lack of efﬁcacy (β=−0.434 [CI: −0.642 to −0.236]), both
p<0.0001), whereas dropouts for other reasons remained
stable (β=−0.014 [−0.243 to +0.216]) over the years. In
contrast, in placebo-arms, dropouts for lack of efﬁcacy
declined markedly over years (β=−1.50 [−1.88 to
−0.1.11]; p<0.0001), whereas dropouts for apparent intol-
erability declined non-signiﬁcantly (β=−0.081 [−0.192
to +0.030]), and dropouts for other reasons remained
stable over years (β=+0.019 [−0.189 to +0.228]).
Relationship of dropout rate to antidepressant efﬁcacy
We used meta-regression modelling to test for association
of particular aspects of dropout rates with effect-size
(SMD). Dropout in placebo-arms associated with lack
of efﬁcacy was highly signiﬁcantly and independently
associated with effect-size, controlling for year, whereas
placebo-dropout associated with intolerability, as well
as antidepressant-associated dropout ascribed to either
intolerability or lack of efﬁcacy were not independently
associated with effect-size (Table 2a). Moreover, dropout
in placebo arms for apparent lack of efﬁcacy remained
highly signiﬁcantly associated with effect-size, controlling
for other factors, including reporting year, trial-size and
nominal trial duration (Table 2b).
Bivariate relationships of placebo-dropout rates
ascribed to lack of efﬁcacy with reporting year and with
effect-size are illustrated in Fig. 2. The placebo-dropout
rates for inefﬁcacy were strongly associated with effect-
size in that lower dropout rates for inefﬁcacy were as-
sociated with much smaller drug-placebo contrasts as
reﬂected in lower SMD values (Fig. 2a), and placebo drop-
outs declined markedly over time (Fig. 2b).
Secondary analyses
We also analysed outcomes of 21 placebo-controlled
RCTs that reported outcomes based on a completer analy-
sis as well as an ITT analysis with LOCF imputing. Based
on ITT analysis, there was a signiﬁcant decrease of effect-
size (SMD) over the years (β=−0.009 [−0.018 to 0.001],
r=0.22, t=2.34, p=0.030, Fig. 3c), corresponding to a sign-
iﬁcant increase in placebo-associated improvement
(SMI-placebo; β=+0.023; [0.011 to 0.036]; p=0.001;
Fig. 3a). Again, improvements associated with antide-
pressant treatment did not change over time. In outcomes
based on completer analysis from the same 21 trials,
no signiﬁcant trends over years were seen for effect-size
(p=0.187, Fig. 3d), placebo-associated improvements (p=
0.264; Fig. 3b), or antidepressant-associated improve-
ments (p=0.636). Moreover, in this subgroup of trials,
ITT based analysis showed a signiﬁcant association be-
tween dropout for lack of efﬁcacy from the placebo arm
and SMD (β=+0.007; [0.001 to 0.014]; p=0.043), as de-
scribed above. However, analysis based on completers
did not show such an association between dropout from
placebo arms for inefﬁcacy and SMD (β=+0.005; [−0.005
to 0.015]; p=0.321).
Egger’s test for publication bias indicated some small-
study effects, although the bias coefﬁcient was not signiﬁ-
cant (1.21 [CI: −0.061 to 2.47]; t=1.91, p=0.062). We also
tested for trends of reporting dropout rates and related
causes, but the proportion of reports including data on
dropout rates (n=56) among 106 trial reports previously
included in a review (Undurraga and Baldessarini,
2012) did not change over the years considered (β=
+0.0008 [−0.009 to +0.010]).
Discussion
We assessed selected factors that might contribute to the
marked decline in apparent efﬁcacy found in
meta-analyses of antidepressant trials in recent decades,
Late
Completed
Other
Intolerability
Inefficacy
Early
Antidepressants
Placebo
42%
53%
78%
80%
13%
12%
13%
13%
13%
3%
39%
3%
22%
7%
6% 4%
LateEarly
Fig. 1. Pie-chart distribution of outcomes in placebo-controlled
trials of antidepressants for antidepressant arms (upper charts)
or placebo arms (lower charts), based on linear regression
modelling for all 56 trials, and reporting estimated values for
the early (1985) and late (2009) observed years. Outcomes:
completed trials as scheduled (white, separated sections),
dropout for intolerability (textured sections), dropout for
apparent lack of efﬁcacy (striped sections), dropout for other
reasons (grey sections), with corresponding mean rates for
representative years: Early (left side) vs. Late (right side)
indicated as percentages.
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guided by ﬁndings in previous reports (Walsh et al., 2002;
Khan et al., 2004, 2010; Undurraga and Baldessarini,
2012). Outcome was based on standardized mean differ-
ence (SMD) in improvements of depression ratings in
antidepressant vs. placebo arms in peer-reviewed, rando-
mized, placebo-controlled antidepressant trials reported
over the past three decades. Like effect-size, dropout
rates have declined strikingly over the era considered
(Figs. 1 and 2). This decrease was signiﬁcant in both
drug- and placebo-arms, but the decrease in placebo-
dropout per year was more than twice greater and was
selectively and robustly associated with declining efﬁcacy
(SMD) in the trials examined. Furthermore, of all reasons
for leaving trials prematurely, only declining dropout for
lack of efﬁcacy of placebo-treatment was independently
and signiﬁcantly associated with decreasing SMD.
The observed major decline of dropout rates in anti-
depressant RCTs is potentially important. Losses of over
20% of subjects pose serious threats to the validity of
results obtained in trials (Schulz and Grimes, 2002), and
have exceeded 50% in trials of some psychotropic agents
(Hutton et al., 2012). In the present trials, dropout rates in
the ﬁrst decade averaged 39.8±11.1% with antidepres-
sants, and 47.7±13.2% with placebo, compared to 24.3±
8.27 and 24.0±9.04%, respectively, in the ﬁnal decade
sampled. Dropout rates have been associated with vari-
ous characteristics of trials, including their design (target
drug vs. active comparator or vs. placebo), type of drug,
geographic area or culture and year of publication
(Vázquez et al., 2011; Kemmler et al., 2005).
The major decrease over years of dropout rates in both
placebo- and drug-arms of antidepressant RCTs is not
readily explained. We did not ﬁnd evidence that the
Table 2. Meta-regression analyses of factors associated with efﬁcacy of antidepressants
a. Association of reasons for dropouts with SMD, controlling for year (n=56)
Factors Slope (β) [95% CI] t-score p-value
Antidepressant dropout rate (%)
Lack of efﬁcacy −0.007 [−0.018 to +0.003] 1.43 0.15
Intolerability −0.001 [−0.007 to +0.005] 0.32 0.75
Other −0.004 [−0.014 to +0.005] 0.92 0.36
Placebo dropout rate (%)
Lack of efﬁcacy +0.009 [+0.004 to +0.015] 3.24 0.002
Intolerability −0.003 [−0.018 to +0.012] 0.35 0.73
Other +0.004 [−0.005 to +0.013] 0.84 0.40
Reporting year −0.005 [−0.013 to +0.002] 1.48 0.14
b. Selected factors associated with SMD (n=56)
Factors Slope (β) [95% CI] t-score p-value
Placebo dropout for inefﬁcacy +0.007 [+0.003 to +0.011] 3.32 0.002
Reporting year −0.006 [−0.014 to +0.001] 1.81 0.08
Trial duration (weeks) +0.010 [−0.013 to +0.032] 0.90 0.37
Subjects/trial (N) +0.00003 [+0.00017 to +0.0002] 0.34 0.74
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Fig. 2. Correlations: (a) Placebo dropout rate (%) ascribed to
lack of efﬁcacy vs. year of reporting, based on linear regression
(β=−1.50 [−1.88 to −1.11]; r=0.728, t=7.83, p<0.0001); (b) SMD
vs. placebo dropout for lack of efﬁcacy based on bivariate
meta-regression (β=+0.009 [0.007 to 0.012]; t=7.11, p<0.0001),
with symbol-size reﬂecting the weight of each study based on
trial-size (N) and standard error of mean effect-size (SMD as
Hedges’ g-statistic).
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apparent nature or severity of the depressive illnesses
studied changed appreciably over the decades. Notably,
there was little change in the probability of having
had previous episodes of depression, in the estimated
duration of the index depressive episodes, or in initial
severity of symptom ratings at trial entry. Indeed, base-
line depression ratings as well as reported demographic
characteristics (sex, age) of subjects have remained stable
and well matched in drug and placebo arms of anti-
depressant trials since 1980. Nevertheless, most trial re-
ports provide very limited clinical information about
characteristics of patients or their illnesses, leaving open
the possibility that some changes over years in patient
or illness characteristics were not identiﬁed or not re-
ported. The decrease in dropouts associated with adverse
effects in drug-arms may plausibly be ascribed to in-
creased tolerability of most modern antidepressants com-
pared to older agents (Baldessarini, 2013). However,
we identiﬁed a within-drug (paroxetine and ﬂuoxetine)
decline of dropouts for intolerability over reporting
years (data not shown), suggesting that mechanisms
other than pharmacological actions were involved.
Longer retention in both drug- and placebo-arms may
reﬂect increasing efforts to limit missing data by encour-
aging subjects to remain in trials (Amery and Dony,
1975; Murray and Findlay, 1988; Streiner, 2002; Wittes,
2009). Dropouts also may be affected by the growing
shift from large trials based in multiple, and often dis-
similar, academic clinics to contract-organization directed
trials based in clinician ofﬁces, typically with relatively
small numbers of subjects-per-site (Hecker et al., 2003).
Such trends may be reﬂected in marked increases in sub-
jects/trial and sites/trial in modern trials for antidepres-
sants and other psychotropic agents [Undurraga and
Baldessarini, 2012; Yildiz et al., 2011a, b). We also found
that subjects/site declined markedly in the present trials
sample. Smaller samples may increase individual atten-
tion and encouragement to remain in trials.
The observed, independent association of placebo
dropout, especially for lack of efﬁcacy, with SMD needs
to be addressed. Ideally, dropouts from trials should be
absent if fair and unbiased conclusions are to be drawn;
however, in most clinical trials, premature dropouts and
missing data are virtually unavoidable (Wittes, 2009).
To deal with missing data because of dropouts, many
trials employ the ﬁnal observation as the endpoint for
each subject (last observation carried forward [LOCF]
method of endpoint-analysis). The LOCF imputation
method assumes that dropout is not related to treatment
or to outcome, and that a subject who discontinues treat-
ment would have retained constant clinical status from
the time of dropout to the planned endpoint (Wittes,
2009). This assumption is highly improbable with de-
pression, especially for dropouts due to lack of efﬁcacy,
which are clearly related to symptom severity. Placebo-
treated patients who drop out for lack of perceived
beneﬁt may be more depressed, with higher symptom
rating scores at the time of dropout than drug-treated
subjects. In contrast, changes in dropout from drug-arms
(mainly for intolerance) appeared to be less associated
with SMD, was ascribed largely to adverse effects or
drug-intolerance and were less associated with SMD
than were declining dropouts with placebo, mostly for
lack of beneﬁt. It would be of interest to know the relative
latency to dropout with placebo vs. active drug-treatment.
However, trial reports rarely provided precise retention
times in each trial arm. Dropout for intolerance may
occur across all illness severities, whereas dropout after
randomization to placebo is more likely with greater
illness-severity; such differences might contribute to
greater effects of longer retention in placebo-arms on
reported effect-size. Furthermore, intolerance associated
with antidepressant treatment might compromise
blinding and enhance expectations of treatment and so
encourage reporting of lower symptom severity in anti-
depressant arms (Greenberg et al., 1994; Baethge et al.,
2013).
Subjects in antidepressant trials are, on average, likely
to improve spontaneously over time, due to the natural,
time-limited course of acute depressive episodes, with
regression-to-the-mean effects that would tend to dimin-
ish drug-placebo contrasts over time. Therefore, dropouts
from placebo-arms for lack of efﬁcacy may lead to
underestimating placebo-associated responses, whereas
dropouts for intolerance may have less inﬂuence on
drug-associated responses. We propose that such dispari-
ties in reasons for dropping out may result in bias that can
lead to the impression that drug-placebo differences are
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Fig. 3. Correlations: (a) Placebo standardized mean
improvement (SMI-Placebo; mean/SD) vs. year of reporting,
based on ITT analyses (β=−0.008 [0.011 to 0.036], r=0.66, t=
3.83, p=0.001). (b) Placebo standardized mean improvement
(SMI-Placebo) vs. year of reporting, based on completer analyses
(β=0.023 [−0.006 to 0.022]; r=0.26, t=1.15, p=0.30). (c) SMD
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analyses (β=−0.009 [−0.018 to 0.001], r=0.22, t=2.34, p=0.030).
Placebo dropout and antidepressant efﬁcacy 1349
 by guest on N
ovem
ber 15, 2016
http://ijnp.oxfordjournals.org/
D
ow
nloaded from
 
greater than they would be if subjects were consistently
observed to the planned trial endpoint. Over the past
three decades a decrease in rates of placebo-dropouts
for lack of efﬁcacy in antidepressant trials would corre-
spond with a decline in carrying forward relatively high
symptom scores as a surrogate outcome measure follow-
ing dropout. Such temporal trends may have contributed
to an increase of mean placebo-associated responses
and decline in drug-placebo differences, as we found.
Such effects are particularly likely when trial outcomes
data are based on ITT analysis employing LOCF as a
way of attempting to deal with missing values (Hennen,
2003).
In a secondary analysis, we compared trends of effect-
size based on ITT analysis (based on LOCF) vs. completer
analysis in studies reporting both analyses (Fig. 3). We
found a signiﬁcant increase in measured improvements
in placebo arms of these trials using ITT-based data, but
not when completer data were used. That is, ITT-based
analyses selectively yielded declining effect-size over
the years. In addition, dropout for lack of efﬁcacy was
not associated with completer-based placebo-associated
responses, whereas in the same set of trials it was signiﬁ-
cantly associated with ITT-based placebo-associated
responses. These considerations indicate that changes in
effect-size over time in antidepressant–placebo compari-
sons depend on the methods of analysis used. Although
the proportion of completers in the placebo arms of
trials increased (Fig. 1), on average they did not show
signiﬁcantly greater improvement over the past three
decades (Fig. 3b). When missing data were carried for-
ward in LOCF-based ITT analyses, subjects randomized
to placebo-treatment did seem to do better over the
past three decades, whereas in completer-based analyses
they did not, and their outcomes approached the
completer-based mean (Fig. 3).
We do not suggest that completer analysis is a superior
method of analysis of trials data, but considered it to com-
pare trends when carrying forward of missing data was
allowed or not. Limitations of completer analyses include
loss of power and probable erosion of initial randomiza-
tion, with potentially unrepresentative samples of remain-
ing subjects who complete trials (Tierney and Stewart,
2005). Although ITT analysis has often been preferred
(Tierney and Stewart, 2005), LOCF methods are far from
an ideal way to manage missing data, because, as found
in the present analysis, the assumption that patients re-
main clinically stable from the moment of dropout to
the trial protocol endpoint usually is not met, resulting
in risk of imputing greater morbidity after earlier drop-
out. In order to overcome this problem, other likelihood-
based analytical methods to account for missing data
such as mixed-effect modelling of repeated measures
(MMRM) have been recommended, or subjects have
been followed-up to assess outcomes even after they
have dropped out of trials (Moher et al., 2001; Hennen,
2003; Lane, 2008; Rabinowitz and Davidov, 2008;
Siddiqui et al., 2009; Little et al., 2012). However, such
methods have become even partially accepted only re-
cently, and many meta-analyses of antidepressant efﬁc-
acy are based on trials using ITT analysis based on
LOCF methods and this choice may lead to identifying
trends of declining efﬁcacy and overestimating pooled
effect-sizes or drug-placebo contrasts.
This study has several noteworthy limitations. One is
that we considered ﬁndings in peer-reviewed, archival
reports. Although we did not ﬁnd evidence of publication
bias, this selection option may under-represent trials with
relatively low drug-placebo contrasts and high placebo-
associated responses (Turner et al., 2008; Baldessarini,
2013). However, obtaining unpublished data from anti-
depressant trials completed as long ago as the 1980s is
virtually impossible and might well risk introducing
time-based bias by selective inclusion of unpublished
data from recent years. In addition, reports that did not
provide dropout rates were not included. This limitation
led to exclusion of 27.9% of otherwise eligible trials,
although there was no change over reporting years in
the proportion of trials reporting on dropouts within
the present sample.
A major limitation that confounds efforts to analyse
ﬁndings from controlled trials generally is that most
reports do not provide speciﬁc information concerning
individual or average retention times in each trial-arm
and their association with morbidity ratings, except at
endpoints arising from ITT and LOCF methods of analy-
sis. This paucity of information limited our ability to
evaluate effects of dropout based on time-in-trial so as
to reﬁne interpretation of declining dropout rates. This
lack of information also limited our ability to include or
conduct MMRM based analyses, for comparison with
LOCF based analyses. Also, some trials were included
that involved small proportions of bipolar depressed
patients, who may be less responsive to antidepressants
(Pacchiarotti et al., 2013). However, the proportion of sub-
jects (0.2%) with bipolar depression was small and un-
likely to bias the present analyses. Finally, we did not
consider all factors previously associated with declining
effect-sizes observed on antidepressant trials as reviewed
above (Introduction), because of uneven reporting of such
factors and limited statistical power with which to test
for independent association of effect-size with a large
number of potentially relevant factors.
In conclusion, among various factors that may impact
measurements of antidepressant efﬁcacy in randomized,
placebo-controlled trials, decreases in dropout rates as-
sociated with placebo-arms of trials were particularly
notable and probably contributed to a decrease of drug-
placebo contrasts (effect-size) over the years since 1980.
We propose that lowering dropout rates in placebo-arms
of trials, speciﬁcally for lack of efﬁcacy, tends to reduce
drug-placebo differences found with ITT- and LOCF-
based analyses that might be avoided by more routine
use of alternative, likelihood-based, outcome analyses
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such as mixed-effect modelling. Decreases in dropout
rates probably have contributed to the decline in apparent
efﬁcacy of antidepressants over the years, as identiﬁed in
this and previous meta-analyses. In short, placebo drop-
out rates complicate meta-analyses of trials and should
be considered among factors inﬂuencing estimates of
effect-size in future reviews.
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